Chronic Myeloid Leukemia.doc

of 24
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Chronic Myeloid Leukemia Also called: Chronic granulocytic leukemia, Chronic myelogenous leukemia, CML Share on facebook Share on twitter Bookmark & Share Printerfriendly !ersion Subscribe to SS Leukemia is cancer of the white blood cells# $hite blood cells hel% your body fight infection# &our blood cells form in your bone marrow# 'n leukemia, the bone marrow %roduces abnormal white blood cells# (hese cells crowd out the healthy blood cells, making it hard for blood to do its work# '
  Chronic Myeloid Leukemia Also called: Chronic granulocytic leukemia, Chronic myelogenous leukemia, CML Share on facebook Share on twitter Bookmark & Share Printerfriendly !ersion Subscribe to SS Leukemia is cancer of the white blood cells# $hite blood cells hel% your body fight infection# our blood cells form in your bone marrow# 'n leukemia, the bone marrow  %roduces abnormal white blood cells# (hese cells crowd out the healthy blood cells, makingit hard for blood to do its work# 'n chronic myeloid leukemia )CML*, there are too many granulocytes, a ty%e of white blood cell#Most %eo%le with CML ha!e a gene mutation )change* called the Philadel%hia chromosome#Sometimes CML does not cause any sym%toms# 'f you ha!e sym%toms, they may include: ã +atigue ã $eight loss ã  ight sweats ã +e!er  ã Pain or a feeling of fullness below the ribs on the left side(ests that e-amine the blood and bone marrow diagnose CML# (reatments include chemothera%y, stem cell trans%lants, infusion of donated white blood cells following stem cell trans%lants, surgery to remo!e the s%leen, and biologic and targeted thera%ies# Biologic thera%y boosts your body.s own ability to fight cancer# (argeted thera%y uses substances that attack cancer cells without harming normal cells# '/: ational Cancer 'nstitute 0et Chronic Myeloid Leukemia u%dates by email   $hat.s this1  ã Start Here o Chronic Myelogenous Leukemia )P23*: (reatment)ational Cancer 'nstitute* o Also a!ailable in S%anish  o $hat 's Chronic Myeloid Leukemia1)American Cancer Society*  o Also a!ailable in S%anish  Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics) Authors obert S egrin, M2 Charles A Schiffer, M2Section 4ditor ichard A Larson, M22e%uty 4ditor ebecca + Connor, M2  Ad by BlockTheAdApp. More Info | Hide These Ads C/ 5'C M4L5'2 L4674M'A 584 8'4$Chronic myeloid leukemia )also called CML or chronic myelogenous leukemia* is a chronic )longterm* disorder of the bone marrow# Bone marrow is the s%ongy, red tissue that fills the large bones# All of the blood cells are %roduced in the bone marrow#Peo%le with CML ha!e ac9uired an abnormality that causes a section of one chromosome )a strand of genes* to break off and attach to another chromosome this results in an abnormally short chromosome, known as the Philadel%hia chromosome# (his e-change of genetic information causes two genes, BC and ABL, to fuse into one gene, called BC ABL#(he BC ABL gene causes bone marrow cells to %roduce an abnormal en;yme )the BC ABL tyrosine kinase* this en;yme stimulates white blood cells to grow out of control, resulting in ele!ations of the white blood cell count and an increase in the si;e of the s%leen# 4!entually, the disease can transform into a more aggressi!e disease, called acute leukemia#Peo%le with acute leukemia ha!e an increased number of immature white blood cells )called blast cells*# (he o!ergrowth of blast cells leads to an inade9uate number of mature white blood cells, which limits %roduction of other !ital blood cells, including red blood cells and %latelets# /a!ing a decreased number of blood cells and %latelets can increase the risk of de!elo%ing infections or bleeding e-cessi!ely#P/AS4S 5+ C/ 5'C M4L5'2 L4674M'A(here are three %hases of CML:Chronic %hase < 'n the chronic %hase, there are less than = %ercent immature blast cells in the bone marrow# A%%ro-imately >= %ercent of %eo%le are in the chronic %hase when they are initially diagnosed# (his %hase generally lasts se!eral years and is readily controlled with oral medications#  Accelerated %hase < 2uring the accelerated %hase, maturation of white blood cells  becomes %rogressi!ely im%aired, and there are between ?@ and ? %ercent blast cells in the  blood or bone marrow# (he number of abnormal cells in the body is more difficult to control with medications, likely because of new mutations that de!elo% in the blast cells#Blast %hase < 'n blast crisis )blast %hase*, there are more than @ to @ %ercent blast cells in the blood or bone marrow# Before recent ad!ances in treatment, blast crisis ty%ically occurred within four to fi!e years after diagnosis and was often unres%onsi!e to treatment#C/ 5'C M4L5'2 L4674M'A ( 4A(M4( 5P('5S(reatment decisions for %eo%le with chronic myeloid leukemia )CML* are com%le- due to the !ariety of a!ailable o%tions# Currently, the most fre9uently used treatment o%tions include:D2isease control with oral tyrosine kinase inhibitors )(7's* such as imatinib )brand name: 0lee!ec*, dasatinib )brand name: S%rycel*, or nilotinib )brand name: (asigna*DPotential cure with hemato%oietic cell trans%lantation )also called bone marrow trans%lantation*, usually after the disease sto%s res%onding or rela%ses during treatment witha (7'D(reatment to reduce sym%toms with chemothera%y )hydro-yurea, busulfan, or interferon al%ha with or without cytarabine*(he choice of thera%y de%ends u%on the %hase of CML, the a!ailability of a stem cell donor, the %atient.s candidacy for stem cell trans%lantation, and the %atient.s %reference# es%onse to treatment < (he %rimary goal of treatment is to reduce or eliminate the cells with the abnormal Philadel%hia chromosome# (his is measured as the cytogenetic response # Such treatment, if effecti!e, will also return the blood counts to normal# (his is measured as the hematologic response #$hile achie!ing a hematologic res%onse will reduce the se!erity of sym%toms associated with CML, %rogression to the accelerated or blast %hase will continue unless a cytogenetic res%onse is achie!ed# Achie!ing a hematologic res%onse is im%ortant, but does not ensure that the disease is ade9uately controlled#Another way to determine how well the disease is controlled is to %erform sensiti!e molecular testing# A %erson is said to ha!e a com%lete molecular response  when there is noe!idence of the BC ABL gene# (he goal of hemato%oietic cell trans%lantation is to achie!e this le!el of res%onse# A molecular res%onse is sometimes seen during longer term follow u% of %eo%le treated with (7's# Chemothera%y rarely, if e!er, %roduces such a res%onse#( 5S'4 7'AS4 '/'B'(5 S )(7's*  (he Philadel%hia chromosome, characteristic of chronic myeloid leukemia )CML*, gi!es rise to the formation of a uni9ue gene %roduct, an abnormal en;yme called the BC ABL tyrosine kinase# esearchers directed their efforts at de!elo%ing com%ounds that could selecti!ely inhibit this abnormal en;yme, resulting in the de!elo%ment of a class of medications known as tyrosine kinase inhibitors )(7's*# (7's slow or sto% the actions of BC ABL, which leads to the ra%id death of cells containing the abnormal Philadel%hia chromosome# ormal cells suffer fewer to-ic effects from (7's com%ared with traditional chemothera%y treatments#Although they ha!e not been %ro!en to cure the disease, (7's are able to achie!e longtermcontrol of CML in the maEority of %eo%le thus, they ha!e become the initial treatment of choice for almost all %eo%le who are newly diagnosed with CML# All of the a!ailable (7's are able to induce hematologic and cytogenetic res%onses in all stages of the disease F?G# As a result, a choice among these medications is usually based u%on the %atient.s medical history and the %otential side effects of each medication )table ?*#Many %rescri%tion and non%rescri%tion medications can interact with (7's, %otentially making the treatment less effecti!e or dangerously increasing the amount of drug in the  bloodstream# (wo non%rescri%tion medications that should be a!oided are acetamino%hen )brand name: (ylenol* and St# Hohn.s wort )also called hy%ericum %erforatum*# 0ra%efruit  Euice should also be a!oided#'matinib )brand name: 0lee!ec* < 'matinib mesylate is a (7' that can be used in %eo%le with all %hases of CML# 't is %ro!en to ha!e significant benefits# 5ne study com%aring imatinib !ersus interferon %lus cytarabine )a form of chemothera%y* for %eo%le with newly diagnosed, chronic %hase CML found that I %ercent of %eo%le who were gi!en imatinib had a com%lete hematologic res%onse rate, and IJ %ercent achie!ed a com%lete cytogenetic res%onse F?G#+urther followu% is needed to determine how long res%onses will last, although the rela%se rate has been remarkably low in %eo%le followed for se!en or more years who achie!ed a com%lete cytogenetic res%onse# At %resent, e-%erts recommend continuing imatinib treatment indefinitely because the disease recurs, often within months, in the maEority of  %eo%le who sto% taking it# Progression to blast crisis can occur des%ite imatinib treatment in %eo%le with accelerated %hase disease and in those who ac9uire new genetic mutations#(he medication should be taken by mouth once daily, with a meal and a large glass of water#'t is e-tremely im%ortant to take e!ery single scheduled dose of your imatinib# Ski%%ing  %ills can seriously Eeo%ardi;e your chances of ha!ing a good res%onse# 5ne study showed that you need to take o!er @ %ercent of your %ills to ha!e a chance of a sustained com%lete res%onse FKG# )See (reatment of chronic myeloid leukemia in chronic %hase after failure of initial thera%y, section on . esistance.#*

Scene D

Jul 23, 2017
Similar documents
View more...
Related Search
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks